CLVS - Why Clovis Oncology Zoomed 30% Higher Today
Cancer-focused biotech Clovis Oncology (NASDAQ: CLVS) was a stock on fire Monday. Investors pushed the company's share price up by more than 30% on the day, thanks to highly encouraging clinical trial results for a new indication of its oncology drug Rubraca.
On Sunday, Clovis reported that Rubraca tested very well as a monotherapy for ovarian cancer in the initial part of a phase 3 trial. The company said that the drug improved progression-free survival (PFS) versus placebo across several disease risk sub-groups.
All told, 538 women suffering from high-grade ovarian, fallopian tube, or primary peritoneal cancer took part in the trial.
For further details see:
Why Clovis Oncology Zoomed 30% Higher Today